Study results show improvement in progression-free survival at 22 months.
Kevin W. Chamberlin, PharmD, FASCP, FCPA
Advertisement
Articles by Kevin W. Chamberlin, PharmD, FASCP, FCPA
On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.
The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.
The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.
Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.
Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Injectable HIV Treatment Beats Daily Pills in Adolescent Trial
2
FDA Approves Onswik Weekly Insulin for Adults With T2D
3
Study Finds Reduced Cardiovascular Risk With Hormone Therapy Initiation
4
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
5